An official website of the United States government
          Here’s how you know
        Here’s how you know**Official websites use .gov**A
              **.gov** website belongs to an official government
              organization in the United States.
        **Secure .gov websites use HTTPS**A
              **lock** (
              Locked padlock icon) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.
 Top Utility Nav
        
        
        Asian-Language Resources
        
        Portal en español


Site search Mega Menu
  

        

        Home
                  Health Topics
                                      
    
  Health Topics

    Arthritis and Rheumatic Diseases
          
    Muscle and Bone Diseases
          
    Skin Diseases
          
    All Diseases and Conditions
          
    Publication Catalog
                  Grants & Funding
                                      
    
  Grants & Funding

    Current Funding Opportunities
          
    Supported Scientific Programs
          
    NIAMS-Supported Programs
          
    Applying for a Grant
          
    NIH Policies and Guidance
          
    Peer Review and Grants Administration Resources
          
    Types of Funding Mechanisms (Activity Codes)
                  Labs @ NIAMS
                                      
    
  Labs @ NIAMS

    NIAMS Labs and Core Facilities
          
    Research Faculty
          
    Research Areas
          
    NIAMS Scientific Advances
          
    Training and Career Development
                  Clinical Trials
                                      
    
  Clinical Trials
      
            For Principal Investigators

    Clinical Trial Policies, Guidelines, and Templates
          
    Conducting Clinical Trials
          
    Register with ClinicalTrials.gov

For Patients

What is a Clinical Trial?
	Clinical Trials at NIAMS
	Clinical Trials in the Spotlight
                  News & Events
                                      
    
  Newsroom

    All NIAMS News
          
    NIAMS Newsletters
          
    Meetings & Events
                  About NIAMS
                                      
    
  About NIAMS

    Director's Page
          
    NIAMS Organization
          
    Strategic Plan Fiscal Years 2020-2024
          
    Staff Directory
          
    NIAMS Budget
          
    Partnerships
          
    Contact NIAMS
                  Community Outreach
                                      
    
  Community Outreach

    Bone Health
          
    Joint Health
          
    Muscle, Tendon, and Ligament Health
          
    Skin Health
          
    Health Information For Kids And Young Adults
          
    Health Information For Older Adults/Seniors
          
    Printable Materials for Community Events
          
    Resources in Other Languages
          
    Annual Health Observances
          
    Social Media Resources Breadcrumb
    Home
          Grants & Funding: The NIAMS Extramural Program
          The Role of NIAMS in the Accelerating Medicines Partnership® (AMP®)








The Role of NIAMS in the Accelerating Medicines Partnership® (AMP®) FacebookEmailPrintFacebookEmail     
    Image
              graphic AMP program word cloud
In 2014, the National Institutes of Health, the Foundation for the NIH, the U.S. Food and Drug Administration, pharmaceutical companies, and nonprofit organizations created theAccelerating Medicines Partnership® (AMP®). This program seeks to transform the current model for developing diagnostics and treatments by increasing efficiency, improving the process, and increasing the number and effectiveness of new targeted therapies.Learn more about theAMP Program.NIAMS participates in three AMP programs:**AMP Autoimmune and Immune-Mediated Diseases (AMP® AIM) program**Launched in 2021, AMP AIM broadens and builds upon the earlier AMP RA/SLE program, described below. AMP AIM investigators are studying the cellular interactions and biological pathways that cause inflammation, injury, abnormal function, and clinical disease in rheumatoid arthritis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, and Sjögren’s disease.Learn more aboutAMP AIM.**AMP Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) program**Actively funded from 2014-2022, AMP RA/SLE investigators examined the cell types, gene expression patterns, and signaling molecules that play a role in rheumatoid arthritis (RA) and/or systemic lupus erythematosus (SLE). As the datasets gathered from the program are finalized, they will be added to NIAMS’Arthritis and Autoimmune and Related Diseases Knowledge (ARK) Portal.Learn more aboutAMP RA/SLE.

Image
              chart showing AMP and AMP AIM timeline
**Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP® BGTC)**The BGTC is establishing platforms and standards to speed the development and delivery of customized or “bespoke” gene therapies that could treat millions of people affected by rare diseases, including diseases too rare to be of commercial interest. In May 2023, the Consortium selected eight rare diseases for its clinical trial portfolio.The National Center for Advancing Translational Sciencesis spearheading the effort at NIH.Learn more aboutAMP BGTC.Accelerating Medicines Partnership and AMP are registered service marks of the U.S. Department of Health and Human Services.


Last Updated: December 2023


Back to Top
 About NIAMS
                    Clinical Trials
                    Grants & Funding
                    Health Topics
                    Labs @ NIAMS
              News Room
                    NIAMS Multimedia Library
                    Disclaimer
                    FOIA
                    Contact us
              Privacy Statement
                    Accessibility
                    HHS Vulnerability Disclosure
                    Social Media Moderation Policy
                    NIAMS Archives
        Subscribe to Our E-Newsletters
            Click the button to see different options to sign up for newsletters.
            Click Here to Subscribe
          Follow us on
  
  About NIH
                  Accessibility Support
            FOIA requests
                  No FEAR Act data
            Office of the Inspector General
                  Performance reports
            Privacy Policy